IL17A and myeloid sarcoma: Another therapeutic option for acute relapses in MS and NMOSD is intravenous immunoglobulin (IVIg). In vitro studies have demonstrated that IVIg inhibits the differentiation and amplification of Th17 cells and the production of IL-17A, IL-17F, IL-21, and CCL20 [73].